From: David Stem <1
To: Jeffrey Epstein <jeevacation@gmail.com>
Subject: Fwd: Project Zermatt: co-investor presentation
Date: Thu, 15 Sep 2011 09:14:24 +0000
Attachments: 2011_09_14_Zermatt_-_Presentation_to_equity_co-investors_Final.pdf
Co-Investment to create a leading player in the niche Active Pharmaceutical Ingredients (APIs) market.
Main investor is Ergon Capital the private equity arm of Groupe Bruxelles Lambert SA (owner Alber Fite).
Begin forwarded message:
From: Tommaso Molinaro AiMENi=
Subject: Project Zermatt: co-investor presentation
Date: 14 Se tember 2011 19:51:14 GMT+01:00
To: gc >
Cc: Serge Touati Wolfgang de Limburg >, Emanuele
Lembo < Riccardo Collini '
41
Dear Mr. Stern,
Please find attached the co-investment document on Pharmazell-Farmabios.
Best regards,
Tommaso
Tommaso Molinaro
Ergon Capital Advisors Italy Srl
Piazza San Sepolcro, 1
20123 Milano - Italy
Tel.
Fax.
Mob.
This message (including any attachments) contains confidential information intended for a specific individual and purpose, and
is protected by law. If you are not the intended recipient, you should delete this
message and arc hereby notified that any disclosure, copying, or distribution of this message, or the taking of any action based
on it, is strictly prohibited.
Qucsto documcnto (inclusi gli eventuali allegati) contiene informazioni riservate ad use esclusivo del destinatario. Se avete
ricevuto quests messaggio per errore Vi preghiamo di volerlo au:moll/as informandovi the tutte le informazioni ivi contenutc
sono soggcttc a riservatezza nei termini della vigente legislazione e, quindi, ne a proibita futiliTrasione e diffusions.
EFTA00919082